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ABSTRACT
Objective: The objective of this selective EBM review is to determine whether or not lifitegrast
5.0% ophthalmic solution is effective in improving eye dryness and safe, in terms of ocular
adverse effects, in adults 18 years or older with dry eye disease (DED).
Study Design: Systematic review of three primary double-blinded, randomized placebocontrolled trials that were published in peer-reviewed journals between 2014-2017.
Data Sources: Studies were obtained through the PubMed database based on relevance to the
clinical question and evaluation of patient-oriented outcomes.
Outcomes Measured: Efficacy of lifitegrast treatment was measured based on the eye dryness
score (EDS) obtained from a subject-reported symptom assessment using a 7-item visual analog
scale. Safety of treatment was measured through investigator safety assessments and recording of
adverse events conducted at study visits.
Results: All three analyzed randomized control trials showed a greater reduction in the EDS
with lifitegrast 5.0% ophthalmic solution compared to placebo. In Holland et al., the reduction in
the EDS was 10.7% greater with lifitegrast compared to placebo (p=0.0007). In Sheppard et al.,
the reduction was 17.8% greater with lifitegrast (p=0.0291). In Tauber et al., lifitegrast showed a
12.3% greater reduction (p<0.0001). For the safety assessment, lifitegrast had more ocular
adverse effects (OAE) than placebo, with majority being mild to moderate in severity. In Holland
et al., 39.5% who received lifitegrast had OAE in comparison to 17.8% who received placebo. In
Sheppard et al., 33.7% with lifitegrast had OAE compared to 16.4% with placebo. In Tauber et
al., 63.5% with lifitegrast had OAE compared to 26% with placebo. The NNH was 5 in Holland
et al., 3 in Sheppard et al., and 6 in Tauber et al.
Conclusions: Lifitegrast is slightly more effective than placebo in improving eye dryness, but
not as safe based on the number of OAE. Lifitegrast can be considered a safe monotherapy for
DED based on the efficacy of improving eye dryness and improbability of causing severe OAE.
Key Words: Lifitegrast; Dry Eye Disease; Dry Eyes
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INTRODUCTION
Dry eye disease (DED) is a condition caused by inadequate quality or quantity of tear
production necessary for lubrication of the eye surface which results in eye dryness, discomfort,
irritation, burning, visual disturbances, and foreign body sensation. The ocular discomfort and
impairment in visual acuity that occurs due to DED leads to a significant impact on quality of
life. This condition can also be referred to as keratoconjunctivitis sicca, dysfunctional tear
syndrome, and dry eye syndrome. Common risk factors include female gender, advancing age,
hormonal alterations, systemic diseases, use of contact lenses, medications including
antihistamines and anticholinergics, vitamin and nutritional deficiencies, ocular surgeries, and
low environmental humidity. DED can also be associated with Sjogren’s syndrome, a chronic
inflammatory condition affecting lacrimal and salivary gland functioning.
The etiology of dry eyes is multifactorial and complex, resulting from a dysfunction in
the interaction between the lacrimal glands, ocular surface, and the eyelids that leads to an
inflammation of the ocular surface and hyperosmolarity of the tear film.1,2 The pathophysiology
of DED can be classified as either an increased evaporative loss of tears or a decreased tear
production. The increase in tear film evaporation often results from meibomian gland
dysfunction, decreased blinking, or structural abnormalities of the eyelids.2 Decreased tear
production occurs secondary to destruction or dysfunction of the lacrimal glands.2 Adequate tear
production by the lacrimal glands and proper evaporation of the tear film is necessary for
adequate visual acuity and cleansing of the eye surface. Any disruption in these two processes
leading to inflammation of the eye surface or hyperosmolarity of the tear film causes an
activation of sensory nerve fibers on the ocular surface resulting in the symptoms of eye
irritation and discomfort.2
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DED currently affects approximately 16.4 million people in the United States and is one
of the most common reasons for ophthalmology visits.3,4 However, the evaluation and diagnosis
of DED can also be performed in an outpatient primary care or emergency setting by physicians
and physician assistants. The diagnosis is based on an evaluation of patient-reported symptoms
and observation of the eyes on physical exam. On examination, notable findings include
conjunctival injection, excess tearing, entropion or ectropion, blepharitis, reduction in blinking,
and visual impairment on acuity testing. A referral to the ophthalmologist is recommended if the
etiology of symptoms is unclear, there is no improvement or relief with treatment, or severe pain
or vision loss occurs.
The overall expenses for DED continues to rise annually and are based on the cost of
frequent visits to healthcare providers, pharmacologic therapy, and non-pharmacologic therapy.
Overall direct and indirect annual cost to the healthcare system in the United States was
estimated at $55.4 billion, with a direct cost equivalent to $738 per person per year. 5 Cost to
society is currently estimated at $11,000 per patient per year. 5 Aside from the financial burden
for the treatment of symptoms, DED also accounts for lost productivity in terms of absence from
work or working with discomfort or altered visual acuity.6
The goal of treatment of DED is to increase or supplement production of tears, slow
evaporation of tears, reduce the resorption of tears, and reduce the inflammation of the ocular
surface.7 First line treatment includes artificial tear supplementation with ophthalmic gels,
ointments, and solutions, and the use of environmental strategies of coping which include
frequent blinking, minimal exposure to air condition and heat, and use of humidifiers. Other
treatments include nutritional supplements, topical or systemic corticosteroids, topical
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cyclosporine, and punctal plugs. These current treatments specifically target symptomatic relief
from DED only.
Lifitegrast 5.0% ophthalmic solution is a new topical eye drop formulation that targets
the underlying ocular surface inflammation and damage that causes DED. It was recently FDA
approved as an integrin antagonist that functions to decrease T cell-mediated inflammation. This
method was proposed as a new treatment because it has a dual mechanism of treating the
underlying pathophysiology and providing symptom relief, unlike the other current treatment
options. Therefore, lifitegrast may provide better long-term symptom relief and be beneficial in
patients refractory to the current treatments.
OBJECTIVE
The objective of this selective EBM review is to determine whether or not lifitegrast
5.0% ophthalmic solution is effective in improving eye dryness and safe, in terms of ocular
adverse effects, in adults 18 years or older with dry eye disease.
METHODS
The articles used for this systematic review were selected based on relevance to the
clinical question and evaluation of patient-oriented outcomes. Articles were obtained through
PubMed database using the keywords “Dry Eye Disease,” “Lifitegrast,” and “Dry Eyes.” The
articles included were written in English and published in peer-reviewed journals between 20142017. Articles were excluded if published before 2008, written in languages other than English,
or evaluated outcomes that were not patient oriented.
This review evaluates three primary double-blinded, randomized placebo-controlled trials
(RCTs). All three trials evaluated the efficacy, based on improvement of eye dryness, and safety,
based on ocular adverse effects, of lifitegrast 5.0% ophthalmic solution in comparison to
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Table 1 - Demographics & Characteristics of Included Studies
Study

Type

#
Pts

Age
(yrs)

Inclusion Criteria

Exclusion Criteria

W/D

Interventions

Holland
et al.,
20168

RCT

711

1893

Sheppard
et al.,
20149

RCT

588

2091

Tauber et
al., 201510

RCT

718

1997

≥18 years old with hx of
DED plus all of the
following: VA ≥0.7
logmin angle of res from visit 1,
fluorescein staining 2+ in
1+ region in ≥ 1 eye,
VASEDS 40+ b/l,
conjunctival redness +1 in
at least one eye, artificial
tear use 30 days before
screening, and positive
response (≥1 eye)
meeting the following at
visits 1 & 2: ICSS 0.5+
and unanesthetized
Schirmer Tear Test
between 1-10 mm.
Immunocompetent
individuals with
secondary Sjögren’s
syndrome not on systemic
steroids.
≥18 years old with hx of
DED, artificial tear use
within past 6 months,
presence of conjunctival
redness, corneal
fluorescein staining 2+
(any field in any eye),
unanesthetized Schirmer
tear test between 110mm, and VA ≥0.7
logmin angle of res b/l.
≥18 years old with hx of
DED, artificial tear use in
past 30 days, VA ≥0.7
logmin angle of res, fluorescein
staining 2+ in ≥1 eye
region, conjunctival
redness 1+ in ≥1 eye,
EDS ≥40, and positive
response (≥1 eye)
meeting the following at
visits 1&2: ICSS ≥0.5 and
unanesthetized Schirmer
tear test between 110mm.
Immunocompetent
individuals with
secondary Sjögren’s
syndrome not on systemic
steroids.

Pregnancy, hypersensitivity to
product, previously in a
lifitegrast trial, use of
medication for blepharitis or
meibomian gland disease
during study, ocular infection
30 days prior to screening,
significant blood loss 56 days
prior to screening, ocular
conditions/chronic illnesses,
immunodeficiency, ocular
surgery in past 12 months, laser
capsulotomy in past 6 months,
alcohol/drug abuse, contact use
during study, and DED
secondary to scarring or
destruction of conjunctival
goblet cells. All other
ophthalmic medications were
prohibited during study.

74

Lifitegrast
5.0%
ophthalmic
solution BID
(upon
wakening
and before
bedtime)
single drop
each eye for
84 days

Contraindications or
hypersensitivity to product,
active ocular inflammation by
slit-lamp exam, active ocular
infection, ocular surgery in past
12 months, contact use during
study, and pregnancy. All other
ophthalmic medications were
prohibited during study.

23

Lifitegrast
5.0%
ophthalmic
solution 1
drop per eye
BID
(morning
and evening)
for 84 day
study period

Pregnancy, contraindications or
hypersensitivity to product,
previous lifitegrast therapy, use
of medication for blepharitis or
meibomian gland disease,
ocular infection within previous
30 days, blood loss in previous
56 days, ocular
conditions/chronic illnesses,
immunodeficiency, ocular
surgery within previous 12
months, laser capsulotomy in
previous 6 months,
alcohol/drug abuse, contact use
during study, and DED
secondary to scarring or
destruction of conjunctival
goblet cells. All other
ophthalmic medications,
antihistamines, and aspirin were
prohibited during study.

49

BID dosing
of lifitegrast
5.0%
ophthalmic
solution
(morning
and before
bed), single
drop each
eye
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placebo. The study population includes adults over the age of 18 with a history of dry eye
disease. Statistics reported in the articles included mean change from baseline, NNH, RBI, ABI,
and p-values. Table 1 displays the demographics & characteristics of the included studies.
OUTCOMES MEASURED
All three RCTs measured the efficacy of lifitegrast in comparison to placebo using an eye
dryness score (EDS). The EDS was obtained from a subject-reported assessment using a 7-item
visual analog scale (VAS). The VAS was scored on a 0-100 scale with 0 referring to no
discomfort and 100 referring to maximal discomfort.8,9,10 In all three studies, the 7 items included
eye dryness, itching, burning/stinging, eye discomfort, foreign body sensation, pain, and
photophobia. All studies also asked participants to subjectively rate each of these items on a
horizontal scale from 0-100 with a single score for both eyes. This efficacy assessment was
completed on day -14 (screening visit), 0, 14, 42, and 84. The primary efficacy point of the
Holland and Tauber studies was the EDS obtained from the VAS. In the Sheppard study, the
EDS obtained from the VAS was a supportive subjective efficacy end point.
The safety of lifitegrast compared to placebo was also measured throughout each of the
three RCTs. Investigator safety assessments and recordings of adverse ocular effects were
conducted at all study visits after the first dose of lifitegrast. The investigator of each study
assessed the self-reported adverse ocular effects of the study drug and placebo for severity. The
severity was rated as mild, moderate, or severe. The most common ocular adverse events that
were reported by participants included reduced visual acuity, instillation site irritation/burning,
and instillation site reaction.8,9,10 This systematic review will focus on the results from day 84 of
each of the trials.
RESULTS
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The efficacy and safety of lifitegrast 5.0% ophthalmic solution in comparison to placebo
was evaluated in all three RCTs. The study period for each of the trials was 12 weeks in duration.
Majority of the participants in each of the trials were female and Caucasian. In all three RCTs,
participants in the lifitegrast group received a single drop of lifitegrast 5.0% ophthalmic solution
in each eye twice daily, once upon wakening and once before bedtime, for 84 days. Participants
in the placebo group followed this same schedule with a matched placebo ophthalmic solution.
At the beginning of each of the trials, participants were given a vial of the investigational product
or placebo. Participants returned the vial at each visit for assessment of compliance with
treatment. In all RCTs, participants who discontinued the study were analyzed using the last
observation carried forward.
In the Holland et al. study, 711 participants between the ages of 18 to 93 with a history of
DED were included in the study and randomized into the lifitegrast group (n=355) or the placebo
group (n=365).8 Six hundred and thirty-seven participants completed the trial. Of the
participants, 96.5% in the lifitegrast group and 97.6% in the placebo group were compliant with
treatment. Participants were considered noncompliant if they took less than 20% or more than
80% of the expected treatment doses between visits and were withdrawn from the study if this
occurred twice.
The mean change in baseline of the EDS on day 84 of the trial was approximately -37 for
the lifitegrast group (54.2% reduction) and -30 for the placebo group (43.5% reduction). This
resulted in a treatment effect of 7 which indicated that participants in the lifitegrast group had a
7-point greater reduction (10.7%) in the EDS from baseline than the placebo group. The
treatment effect was statistically significant, indicated by a p-value of 0.0007, and precise, with a
narrow 95% CI of 3.04-11.28.8 Refer to Table 2 for the efficacy results of this study.

Cole, Lifitegrast for Dry Eye Disease 7
In the Holland et al. study, the number of overall ocular adverse effects in the lifitegrast
group was greater than the placebo group, as shown in Table 3. Of the participants, 17.8% in the
placebo group and 39.5% in the lifitegrast group reported ocular adverse effects ranging in
severity of mild, moderate, or severe. Of the ocular adverse effects in the lifitegrast group, 31.7%
were mild, 7.3% were moderate, and 0.6% were severe. According to the NNH, for every 5
patients treated with lifitegrast, 1 additional person will have a mild, moderate, or severe ocular
adverse effect. The safety results of this study are reported in Table 4.
Table 2: Comparison of Efficacy of Lifitegrast vs Placebo based on the Mean Change from
Baseline of the EDS
Mean Change from Mean Change from Treatment Effect
Baseline on day 84 Baseline on day 84
(Lifitegrast)
(Placebo)
RCT
Numerical Percent Numerical Percent Numerical Percent 95% P-value
CI
Holland et
-37
54.2%
-30
43.5%
7
10.7% 3.04- 0.0007
al.8
11.28
Sheppard
-15.2
37.8%
-10.6
25.5%
4.6
12.3%
0.0291
9
et al.
Tauber et
-35.3
50.7%
-22.75
32.9%
12.55
17.8% 8.51- <0.0001
10
al.
16.7

The Sheppard et al. study included 588 participants between the age of 20-91 years old
with a history of DED. Five hundred and sixty-five participants completed the study. Participants
were randomized into the placebo group (n=295) and the lifitegrast group (n=293).9 Th mean
change from baseline on day 84 of the trial was -10.6 for placebo (25.5% reduction) and -15.2
for lifitegrast (37.8% reduction). The treatment effect was 4.6, indicating a 4.6-point greater
reduction (12.3%) in EDS with lifitegrast. The treatment effect was statistically significant based
on the p-value of 0.0291.9 The efficacy results of this study are shown in Table 2.
Lifitegrast was shown to cause more mild, moderate, and severe adverse ocular effects
than placebo. Of the participants in the lifitegrast group, 63.5% developed ocular adverse effects,
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in comparison to 26% in the placebo group, as shown in Table 3. Of the participants in the
lifitegrast group who developed ocular adverse effects, 56% were mild, 7% moderate, and 0.5%
severe. The calculated NNH indicated that 1 additional person will develop adverse ocular
effects for every 3 treated with lifitegrast. The safety results of this study are shown in Table 4.
Table 3: Percentage of Participants who Experienced Ocular Adverse Effects
(Combination of Mild, Moderate, and Severe)
RCT
Lifitegrast
Placebo
Holland et al.8
39.5%
17.8%
9
Sheppard et al.
63.5%
26%
10
Tauber et al.
33.7%
16.4%

In the Tauber et al. study, 718 subjects from the ages of 19 to 97 years old with a history
of DED were analyzed. Participants were randomized into the placebo group (n=360) or the
lifitegrast group (n=358).10 Forty nine of the total participants discontinued the study before day
84. Of the participants, 95.5% in the placebo group and 93% in the lifitegrast group were
compliant with treatment. Participants were considered noncompliant if greater than 20% of the
expected dose was missed since the previous visit or greater than 120% of the expected dose was
taken.
The mean change from baseline on day 84 was -22.75 in the placebo group (32.9%
reduction) and -35.3 in the lifitegrast group (50.7% reduction), resulting in a treatment effect of
12.55. This indicates that participants in the lifitegrast group had a 12.55-point (17.8%) greater
reduction from baseline in the EDS than those in the placebo group. The treatment effect was
significant based on the p-value of <0.0001 and precise, based on the 95% CI of 8.51-16.70.9
The efficacy results of this study are shown in Table 2.
In terms of safety, lifitegrast caused mild, moderate, or severe adverse ocular effects in
33.7% of participants in comparison to 16.4% in the placebo group, as shown in Table 3. Of the
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ocular adverse effects that occurred in the lifitegrast group, 84% were mild, 8.6% were moderate,
and 1.7% were severe. According to the NNH, for every 6 patients treated with lifitegrast, 1
additional person will develop an adverse ocular effect. The safety results of this study are
reported in Table 4.
Table 4: Safety Analysis of Lifitegrast vs Placebo
RCT
Relative Risk
Absolute Risk
Increase (RRI)
Increase (ARI)
Holland et al.2
1.213
0.217
8
Sheppard et al.
1.44
0.375
7
Tauber et al.
1.055
0.173

Number Needed to
Harm (NNH)
5
3
6

DISCUSSION
Lifitegrast, also known by the brand name Xiidra, is a new treatment for the symptoms of
dry eye disease that was approved by the FDA in July of 2016 for individuals 17 and older.
There are currently no other indications for the use of this drug. Lifitegrast is an integrin
antagonist that functions to decrease T-cell mediated inflammation, thought to cause DED.8,9,10 It
is a 5.0% ophthalmic solution that comes in a single use container and currently costs around
$600 per 30-day supply package in the United States. The current dosing regimen is 1 drop in
each eye every 12 hours. Contact lens users are advised to remove the lenses before application
of the solution and wait 15 minutes before reinsertion. Contraindications include hypersensitivity
to lifitegrast or the drug formulation. The most common adverse effects noted include dysgeusia,
irritation at the application site, and decreased visual acuity.8,9,10
Lifitegrast was shown to be slightly more effective in treating eye dryness in compared to
placebo. All three trials showed a small treatment effect based on the mean change from baseline
of the EDS from the self-reported VAS. In each trial, the treatment effect was statistically
significant based on the p-value. According to the NNH and the comparison of the percent of
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individuals with ocular adverse effects between the study groups, lifitegrast was shown to be less
safe than placebo. Although more participants in the lifitegrast group had ocular adverse effects
and the value for the NNH was small in all studies, the ocular adverse effects were mild to
moderate with very few cases being severe. In addition, the adverse effects were not unexpected,
and the most common effects were irritation/burning and site reaction with application, which is
common with any topical ophthalmic solution. The studies did not show any local or systemic
infection from lifitegrast or any long-term effects that would impair quality of life. Based on this
information, lifitegrast appears to be a generally safe treatment method. It can be concluded that
lifitegrast is effective in treating eye dryness and is generally safe in individuals 18 and older
with DED.
Although each of the studies displayed that lifitegrast was effective in improving eye
dryness in individuals with DED, there were limitations based on the populations specifically
studied. Majority of participants in all three trials were Caucasian and female. This caused
limitation in the generalizability of the treatment effect since different races and gender were not
evaluated equally. Also, all three RCTs only included individuals actively or recently using
artificial tear substitutes. The Holland and Tauber RCTs only included individuals with DED that
had used artificial tears for symptomatic relief at least 30 days prior to the study and the
Sheppard study only included those who used artificial tears in the past 6 months. Therefore,
individuals who had discontinued use of artificial tears in the past and were not currently or
recently using artificial tears were excluded from these RCTs. Reasoning for previous
discontinuation of treatment may have been due to ineffective symptom relief from other
methods. With the use of this criteria for participant selection, individuals with long term or
advanced dry eye disease may have been excluded.
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Other limitations were also based on the inclusion and exclusion criteria. The three RCTs
prohibited contact lens use during the study period, therefore individuals who desired to use
contact lenses were excluded. Consequently, the efficacy and safety of this drug cannot be
applied to individuals with contact lenses based on these three RCTs. Participants were also
prohibited from using additional therapy for DED with lifitegrast, including artificial tears or
ophthalmic solutions, during the trial period. Therefore, the efficacy and safety of lifitegrast is
only based on the sole use of lifitegrast as a monotherapy. The antagonistic or synergistic effects
of lifitegrast with other treatment regimens cannot be predicted based on this systematic analysis
of lifitegrast. All three of the trials included a 12-week duration of therapy with lifitegrast. This
limited determination of the long-term effectiveness and safety of the use of lifitegrast for DED.
CONLUSIONS
Lifitegrast 5.0% ophthalmic solution was slightly more effective, but not safer than
placebo in all three RCTs evaluated in this systematic review. Based on the efficacy results for
improving eye dryness and the low probability of severe ocular adverse effects, lifitegrast should
be considered as a new monotherapy for the treatment of eye dryness in patients 18 and older
with DED, especially those who fail other current treatment regimens. Future research studies
should focus on a longer trial period with lifitegrast with more specific attention to the safety
assessment. Research in populations with contact lenses should also be considered. Other future
studies evaluating lifitegrast in combination with other treatment modalities for DED, including
artificial tears, steroids, and other ophthalmic medications, are warranted to determine use of
lifitegrast as an add on or combination medication.
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